Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Relapsed or Refractory Extranodal NK/T-cell Lymphoma
NCT03439501Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jan 2018
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
avelumab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03439501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439501.